Latest Conference Articles

Durvalumab plus BCG induction/maintenance showed a tolerable safety profile in BCG-naive NMIBC, according to the phase 3b PATAPSCO study.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

“The use of GLP-1 drugs [vs] DPP-4 inhibitors…was associated with a meaningful reduction in cancer progression,” Mark David Orland, MD.

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

Early study data show community oncology matches or beats hospital cancer outcomes at lower cost, boosting local access, better experience, and payment reform calls.

“Combining [lutetium Lu 177 vipivotide tetraxetan] with ADT and ARPI increased the frequency and depth of PSA responses," said Fred Saad, MD.

Investigators urge caution in interpreting these results, acknowledging the inherent limitations of unanchored, population-adjusted indirect trial comparisons.

The TRITON3 update supports rucaparib's role as an established option in the post-ARPI, pre-chemotherapy BRCA+ mCRPC setting.

“These findings support the potential for a treatment holiday with enzalutamide combination [therapy] in high-risk biochemically recurrent prostate cancer," said Neal D. Shore, MD.

SunRISe-4: Genomic disease burden, TMB, and PD-L1 expression linked to pathologic overall response to neoadjuvant gemcitabine intravesical system plus cetrelimab in MIBC.

Two preoperative doses of intravesical mitomycin-C administered 1 day and 4 hours before TURBT led to a 5-year RFS rate of over 90% in NMIBC.

The pembrolizumab/BCG combo yielded clinical complete responses at 6 months in over 90% of very high-risk BCG-naive NMIBC patients.

"It's also encouraging that 96.8% of patients were free of progression to muscle-invasive or greater disease,” said Ashish M. Kamat, MD, MBBS.

Combining durvalumab with BCG induction and maintenance therapy significantly reduced the risk of disease recurrence in BCG-naive, high-risk NMIBC.

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

Dr Roberto Borea explores how BMI impacts NSCLC survival and molecular pathways, revealing key T-cell and redox data for IO and TKI treatment cohorts.

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ROS1-positive metastatic NSCLC.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

Darlifarnib may enable the rechallenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer patients from the RUBY trial.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ovarian cancer.

Bradley Monk, MD, discusses the KEYNOTE-B96 trial in which pembrolizumab plus paclitaxel +/- bevacizumab improved OS in platinum-resistant ovarian cancer.